Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Retained Earnings (2019 - 2025)

Beam Therapeutics (BEAM) has disclosed Retained Earnings for 7 consecutive years, with $1.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Retained Earnings rose 63.62% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 63.62% increase, with the full-year FY2025 number at $1.1 million, up 63.62% from a year prior.
  • Retained Earnings was $1.1 million for Q4 2025 at Beam Therapeutics, up from $790000.0 in the prior quarter.
  • In the past five years, Retained Earnings ranged from a high of $1.1 million in Q4 2025 to a low of -$1.5 billion in Q3 2024.
  • A 5-year average of -$580.6 million and a median of -$651.4 million in 2021 define the central range for Retained Earnings.
  • Peak YoY movement for Retained Earnings: crashed 8536277.78% in 2021, then soared 117.37% in 2025.
  • Beam Therapeutics' Retained Earnings stood at -$768.3 million in 2021, then soared by 99.68% to -$2.4 million in 2022, then tumbled by 48866.63% to -$1.2 billion in 2023, then surged by 100.06% to $679000.0 in 2024, then surged by 63.62% to $1.1 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Retained Earnings are $1.1 million (Q4 2025), $790000.0 (Q3 2025), and $10000.0 (Q2 2025).